Dexcom Inc
XMUN:DC4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Economic Moat
Dexcom has a narrow economic moat
Patents covering Dexcom’s glucose-sensing technology make its products harder to copy. Connections to compatible insulin pumps also give some patients a practical reason to stay, because changing sensors can mean changing how their diabetes equipment works together. These protections limit competition without shutting out established rivals such as Abbott.
What protects Dexcom from competitors
Intangible Assets
Dexcom holds patents covering parts of the sensor and protective membrane that help it measure glucose beneath the skin. These rights prevent rivals from freely copying protected designs, requiring them to develop alternatives or obtain permission to use the technology.
High Switching Costs
Dexcom sensors work with compatible insulin pumps that automatically adjust insulin delivery, making the sensor part of a patient’s treatment setup. For patients whose equipment does not support a rival sensor, switching can require equipment or software changes rather than simply buying another brand.
What could weaken Dexcom's moat
Rivals bypass protected designs
A rival that develops equally effective sensors without using Dexcom’s patented designs could compete without being held back by those patents.
Broader rival pump compatibility
Further expansion of Abbott sensor compatibility across insulin pumps could let more Dexcom users switch without replacing equipment or disrupting automated insulin delivery.
Peer Comparison
2 of 6 peers have a wide moat.
Intuitive Surgical ISRG
Wide
High Switching Costs, Intangible Assets
Stryker SYK
Wide
High Switching Costs, Intangible Assets
Abbott Laboratories ABT
Narrow
High Switching Costs, Intangible Assets
Medtronic MDT
Narrow
High Switching Costs, Intangible Assets
Boston Scientific BSX
Narrow
High Switching Costs, Intangible Assets
Edwards Lifesciences EW
Narrow
High Switching Costs, Intangible Assets